¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"dose limiting factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® rheumatoid factor ÇÑ±Û ·ù¸¶Æ¼½º ÀÎÀÚ
¼³¸í   
  IgGÀÇ FcºÎÀ§¿¡ Àִ Ç׿ø°áÁ¤ÀÎÀÚ¿¡ ´ëÇÑ Ç×ü·Î¼­ ÀüÇüÀûÀΠ¶Ç´Â È®½ÇÇÑ ·ù¸¶Æ¼½º°üÀý¿°(rheumatoid arthritis) È¯ÀÚÀÇ 80%¿¡¼­ ¹ß°ßµÈ´Ù. ·ù¸¶Æ¼½º ÀÎÀڴ IgM, IgG, IgAÁß Çϳª°¡ µÉ ¼ö ÀÖÀ¸³ª ÁַΠIgMÀÌ´Ù. ¼Ò¾Æ·ù¸¶Æ¼½º°üÀý¿°(juvenile rheumatoid arthritis: ¼Ò¾Æ±â¿¡ ¹ß»ýÇϴ ·ù¸¶Æ¼½º°üÀý¿°)À» ºñ·ÔÇÑ, ´Ù¸¥ °áÇÕÁ¶Á÷º´À̳ª °¨¿°º´¿¡µµ ³ªÅ¸³¯ ¼ö ÀÖ´Ù
¿µ¹® radiation dose ÇÑ±Û ¹æ»ç¼±·®
¼³¸í   
  ¹æ»ç¼±Á¶»çÀÇ Á¤µµ. ¹æ»ç¼±»ý¹°ÇÐÀ̳ª ÀÎüÀÇ ¹æ»ç¼±¹æÈ£¿¡¼­´Â Àü¸®¹æ»ç¼±ÀÇ ¾ç, Áï ¼±·®ÀÌ ¹®Á¦°¡ µÈ´Ù. ¹æ»ç¼±·®¿¡¼­µµ ±¹Á¦´ÜÀ§°è(SI)°¡ Ã¤¿ëµÇ¾î ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)ÀÇ ±Ç°í¿¡ µû¶ó¼­ ´ÙÀ½ÀÇ ¿©·¯ ´ÜÀ§°¡ ³Î¸® »ç¿ëµÈ´Ù. ¨ç Èí¼ö¼±·®(absorbed dose). ¹°ÁúÀÇ ´ÜÀ§Áú·®ÀÌ ¹æ»ç¼±¿¡ ÀÇÇØ ¹Þ¾ÆµéÀ̴ ¿¡³ÊÁö. ÀÌ ´ÜÀ§´Â ¹æ»ç¼± ¹× ¹°ÁúÀÇ Á¾·ù°¡ ¾î¶°ÇÑ °ÍÀÌ´õ¶óµµ »ç¿ëÇÒ ¼ö ÀÖ´Ù. ±¹Á¦´ÜÀ§´Â J/kgÀ̸ç À̰Ϳ¡ °íÀ¯ÇÑ ¸íĪÀ¸·Î ±×·¹ÀÌ(gray, ±âÈ£ Gy)°¡ ºÎ¿©µÈ´Ù. 1Gy=100¶óµå(rad). ¨è Á¶»ç¼±·®(exposure) ¶Ç´Â °øÁß¼±·®. X¼± ¶Ç´Â ¥ã¼±¿¡ ÇÑÇØ¼­ »ç¿ëµÈ´Ù. ±¹Á¦´ÜÀ§´Â C/kg. ¨é ¼±·®´ç·®(dose equivalent). ¹æ»ç¼±¹æÈ£¸¦ À§ÇØ »ç¿ëµÇ´Â ¾ç. ±âÈ£´Â H. H´Â ¹æ»ç¼±ÀÇ Á¾·ù¿Í ¿¡³ÊÁö¿¡ ÀÇÇØ »ýü¿¡ Áִ ȿ°ú¸¦ º¸Á¤Çϴ ¼±Áú°è¼ö(Q)¿Í ±× ¹ÛÀÇ ÀÎÀÚ(¿¹¸¦ µé¸é ¼±·®·ü, ¹æ»ç¼ºµ¿À§¿ø¼Ò¿¡ ÀÇÇÑ ³»ºÎÇÇÆø½Ã¿¡´Â ±× ÇÙÁ¾ÀǠü³»ºÐÆ÷ µî)¿¡ ±Ù°ÅÇÑ º¸Á¤°è¼ö(N)¸¦ Èí¼ö¼±·®(D)¿¡ °öÇÑ °Í, Áï H=D-Q-N. ¶ÇÇÑ DÀÇ ´ÜÀ§¸¦ Gy ¶Ç´Â rad·Î Ç¥½ÃÇÏ¿´À» ¶§ HÀÇ ´ÜÀ§¸¦ °¢°¢ ½Ãº£¸£Æ®(sievert, ±âÈ£ Sv) ¹× ·½(rem)À̶ó°í ÇÑ´Ù. µû¶ó¼­ 1 Sv=102rem. ÀϹÝÀûÀ¸·Î ´ÜÀ§½Ã°£´çÀÇ ¼±·®À» ¼±·®·ü(dose rate)À̶ó°í ÇÑ´Ù.
¿µ¹® growth factor ÇÑ±Û ¼ºÀåÀÎÀÚ
¼³¸í   
  ¼¼Æ÷ÀÇ ºÐÈ­ ¹× ¼ºÀå¿¡ °ü¿©Çϴ ´Ü¹éÁú. ¼ºÀåÀÎÀڴ Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ Å¾ÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù.
¿µ¹® dose ÇÑ±Û ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
¼³¸í   
  1. ¾àÁ¦¸¦ ÇÑ ¹ø ¶Ç´Â ÇÏ·ç¿¡ »ç¿ëÇϰųª º¹¿ëÇϴ ºÐ·®. 2. ¹°ÁúÀ̳ª Á¶Á÷¿¡ ´ëÇÑ ¹æ»ç¼±ÀÇ ÀÛ¿ë Á¤µµ¸¦ ³ªÅ¸³»´Â ¾ç. Áï, ¹æ»ç¼±·®À̶ó´Â °³³äÀº ¾î¶² ÇÑ Á¡¿¡ ÀÔ»çÇϴ ¹æ»ç¼±°ú ±× Á¡ ±Ùó¿¡ Àִ ¹°Áú¿¡ ´ëÇÑ ¹æ»ç¼±ÀÇ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀû È¿°ú¿ÍÀÇ °ü°Ô¸¦ Á¤·®ÀûÀ¸·Î ³ªÅ¸³»´Â °øÅëÀΠôµµ·Î¼­ »ý°¢µÈ °ÍÀÌ´Ù. ¶óµå(rad)·Î ³ªÅ¸³»´Â Èí¼ö·®, ·»Æ®°Õ(R)À¸·Î ³ªÅ¸³»´Â Á¶»ç ¼±·®, ·½(rem)À¸·Î ³ªÅ¸³»´Â ¼±·® ´ç·®À¸·Î ±¸ºÐÇÏ¿© ¾´´Ù.
¿µ¹® risk factor ÇÑ±Û À§ÇèÀÎÀÚ
¼³¸í   
  ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼­ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î Ã¤ÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£­3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£­3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ À־ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£­3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼­ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» Çϸ鼭 ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£­3/SvÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • glial limiting membrane
    ¾Æ±³°æ°è¸·, ±³¼¼Æ÷°æ°è¸·
  • gradient limiting reabsorption
    ³óµµ°æ»çÁ¦ÇÑÀçÈí¼ö
  • limiting concentration
    ÇѰè³óµµ
  • limiting dilution method
    ÇѰèÈñ¼®¹ý
  • limiting membrane
    °æ°è¸·
  • rate limiting enzyme
    ¼ÓµµÁ¦ÇÑÈ¿¼Ò
  • rate limiting reaction
    ¼ÓµµÁ¦ÇѹÝÀÀ
  • self-limiting
    ÀÚ±âÇÑÁ¤-
  • acceptable daily dose
    ÀÏÀÏÇã¿ë·®
  • average dose
    1. Æò±Õ¿ë·® 2. Æò±Õ¼±·®
  • air dose
    °ø±â¼±·®
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose rate
    Èí¼ö¼±·®·ü
  • biologically effective dose
    »ý¹°ÇÐÀûÀ¯È¿¼±·®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rate limiting enzyme
    ¼ÓµµÁ¶ÀýÈ¿¼Ò
  • self-limiting
    ÀÚ±âÁ¦ÇÑ
  • dose
    ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
  • average dose
    Æò±Õ¿ë·®, Æò±Õ¼±·®
  • booster dose
    Ãß°¡Á¢Á¾·®, Ãß°¡¿ë·®
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • lethal dose
    Ä¡»ç·®
  • maximum dose
    ÃÖ´ë¿ë·®, ÃÖ´ë¼±·®
  • optimum dose
    ÀûÁ¤¿ë·®, ÀûÁ¤¼±·®
  • radiation dose
    ¹æ»ç¼±·®
  • radiation absorbed dose
    Èí¼ö¼±·®
  • skin dose
    ÇǺμ±·®
  • therapeutic dose
    Ä¡·á¿ë·®, Ä¡·á¼±·®
  • high-dose
    °í¿ë·®
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • time-dose factor
    ½Ã°£¼±·®ÀÎÀÚ
  • adjustable pressure limiting valve
    ¾Ð·ÂÁ¦ÇÑÁ¶ÀýÆÇ¸·
  • limiting concentration
    ÇѰè³óµµ
  • limiting dilution culture
    ÇѰèÈñ¼®¹è¾ç¹ý, ´ÜÀϼ¼Æ÷¹è¾ç¹ý
  • limiting dilution
    Á¦ÇÑÈñ¼®
  • rate limiting enzyme
    ¼ÓµµÁ¶ÀýÈ¿¼Ò
  • glial limiting membrane
    ¾Æ±³°æ°è¸·
  • gradient limiting reabsorption
    ³óµµÁõ°¨Á¦ÇÑÀçÈí¼ö
  • limiting line
    ÇѰ輱
  • limiting membrane
    °æ°è¸·
  • limiting dilution method
    ÇѰèÈñ¼®¹ý
  • rate limiting reaction
    ¼ÓµµÁ¦ÇѹÝÀÀ
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose rate
    Èí¼ö¼±·®·ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • adjustable pressure limiting valve
    Á¶ÀýÇü ¾Ð·ÂÁ¦ÇÑ ¹ëºê.
  • anterior limiting membrane
    ¾Õ°æ°èÆÇ
  • gradient limiting reabsorption
    ³óµµÁõ°¨Á¦ ÇѼº ÀçÈí¼ö.
  • inner limiting membrane
    ³»°æ°è¸·.
  • inner limiting membrane
    ¼Ó°æ°èÃþ
  • inner limiting membrane
    ³»°æ°è¸·, ¼Ó°æ°èÃþ.
  • posterior limiting membrane
    µÚ°æ°èÆÇ
  • pressure limiting valve
    ¾Ð·ÂÁ¦Çѹëºê.
  • rate limiting
    ¼ÓµµÁ¦ÇÑÀÇ.
  • rate limiting enzyme
    ¼ÓµµÁ¶ÀýÈ¿¼Ò(áÜöôðàï½ý£áÈ).
  • rate limiting reaction
    ¼ÓµµÁ¦ÇѹÝÀÀ.
  • F factor (fertility factor)
    FÀÎÀÚ, ¼öÅÂÀÎÀÚ
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®, Áß°£À¯È¿·®.
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dose limiting factor
    ¼±·®ÇѵµÀÎÀÚ, ¼±·®Á¦ÇÑÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • time, dose and fractionation factor, TDF factor
    ½Ã°£¼±·®ºÐÇÒÀÎÀÚ
  • limiting factor
    ÇѰèÀÎÀÚ, Á¦ÇÑÀÎÀÚ, ÇÑÁ¤ÀÎÀÚ(¡­ì×í­).
  • limiting factor
    ÇѰèÀÎÀÚ(ùÚÍ£ì×í­), Á¦ÇÑÀÎÀÚ(ð¤ùÚì×í­), ÇÑÁ¤ÀÎÀÚ(¡­ì×í­).
  • cumulative dose ; cumulate dose
    ´©Àû¿ë·®.
  • cumulative dose ; cumulate dose
    ÃàÀû(¿ë)·®, ´©Àû(¿ë)·®, ´©ÀûÁ¶»ç(¿ë)·® , [¿¹¹æ] ÁýÀû¼±·®.
  • cumulative dose ; cumulate dose
    ÃàÀû(¿ë)·®, ´©Àû(¿ë)·®, ´©ÀûÁ¶»ç(¿ë)·® .[¿¹¹æ]ÁýÀû¼±·®.
  • dose rate ; dosage rate ; dose per unit time
    ¹æ»ç ÀÓº´,ÇÙÀÇ,¾à¸®¼±·®·ü, ¿ë·®.
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • optimal dose ; optimum dose
    ¹æ»ç [¾à¸®,ÇØºÎ,¿¹¹æ]ÃÖÀû·®, ÀûÁ¤·®(ËøËøËâ).
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • dose conversion factor
    ¼±·®º¯È¯°è¼ö
  • dose modifying factor
    ¼±·®¼ö½Ä°è¼ö
  • dose-reduction factor
    ¼±·®°¨¼Ò°è¼ö
  • time-dose factor
    ½Ã°£¼±·®ÀÎÀÚ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Limiting plate
    °£¼Ò¿±°æ°èÆÇ
    [¿¾ ¿ë¾î] °£¼Ò¿±°æ°èÆÇ
  • Limiting membrane
    °æ°è¸·
    [¿¾ ¿ë¾î] °æ°è¸·
  • Periventricular glial limiting membrane
    ³ú½ÇÁÖÀ§¾Æ±³°æ°è¸·
    [¿¾ ¿ë¾î] ³ú½ÇÁÖÀ§°æ°è¸·
  • Posterior limiting membrane
    µÚ°æ°èÆÇ
    [¿¾ ¿ë¾î] Èİæ°èÆÇ
  • Outer limiting membrane
    ¹Ù±ù°æ°èÃþ
    [¿¾ ¿ë¾î] ¿Ü°æ°èÃþ
  • External glial limiting membrane
    ¹Ù±ù¾Æ±³°æ°è¸·
    [¿¾ ¿ë¾î] ¿Ü±³°æ°è¸·
  • Inner limiting membrane
    ¼Ó°æ°èÃþ
    [¿¾ ¿ë¾î] ³»°æ°èÃþ
  • Internal glial limiting membrane
    ¼Ó¾Æ±³¼¼Æ÷°æ°è¸·
    [¿¾ ¿ë¾î] ³»±³°æ°è¸·
  • Anterior limiting membrane
    ¾Õ°æ°èÆÇ
    [¿¾ ¿ë¾î] Àü°æ°èÆÇ
  • Superficial glial limiting membrane
    Ç¥¸é¾Æ±³°æ°è¸·
    [¿¾ ¿ë¾î] õ±³°æ°è¸·
  • Perivascular glial limiting membrane
    Ç÷°üÁÖÀ§¾Æ±³°æ°è¸·
    [¿¾ ¿ë¾î] Ç÷°üÁÖÀ§°æ°è¸·
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Duffy factor
    ´õÇÇÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rate-limiting step
    ¼ÓµµÁ¦ÇÑ ´Ü°è(áÜÓøð¤ùÚÓ«Í­)
  • limiting amino acid
    Á¦ÇÑ(ð¤ùÚ)¾Æ¹Ì³ë»ê(ß«)
  • limiting current
    ÇѰèÀü·ù(ùÚÍ£ï³×µ)
  • limiting reagent
    Á¦Çѽþà(ð¤ùÚãËå·)
  • limiting velocity
    Á¦ÇѼӵµ(ð¤ùÚáÜÓø)
  • limiting viscosity number
    Á¦ÇÑÁ¡µµ¼ö(ð¤ùÚïÄÓøâ¦)
  • van't Hoff limiting law
    ¹ÝÆ® È£ÇÁ Á¦ÇÑ ¹ýÄ¢(ð¤ùÚÛööÎ)
  • absorbed dose
    Èí¼ö·® (ýåâ¥Õá)
  • air dose
    ´ë±â¼±·®(ÓÞѨàÊÕá)
  • booster dose
    ºÎ½ºÅÍ ·®(Õá)
  • dose-response curve
    ¿ë·®´ëÀÀ °î¼±(é»ÕáÓßëëÍØàÊ)
  • exposure dose
    ³ëÃâ·®(ÖÚõóÕá)
  • fractionated dose
    ºÐÇÒ·®(ÝÂùÜÕá)
  • half-value dose
    ¹Ý(Úâ)°ª ¼±·®(àÊÕá)
  • lethal dose
    Ä¡»ç·®(öÈÞÝÕá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • attenuation factor
    °¨¾à¿ä¼Ò, °¨¼è¿äÀÎ
  • conversion factor
    º¯È¯ÀÎÀÚ
  • factor
    ÀÎÀÚ
  • predisposing factor
    ¼ÒÀÎ, Áúº´¼ÒÁú
  • Q factor
    Å¥ÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½º¾çÀÎÀÚ
  • risk factor
    À§Çè¿äÀÎ
  • turbo factor
    Åͺ¸ÀÎÀÚ
  • air dose
    °øÁß¼±·®, °ø±âÁß¼±·®
  • cumulative dose
    ÁýÀû¼±·®, ´©ÀûÁ¶»ç·®, ´©Àû¿ë·®, Ãàô¿ë·®
  • curative dose
    ġȿ·®
  • depth dose
    ½ÉºÎ¼±·®
  • dose rate
    ¼±·®·ü
  • fatal dose
    Ä¡»ç·®
  • half lethal dose
    ¹ÝÄ¡»ç·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CF calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ...
ID identification; iditol dehydrogenase; immunodeficiency; immunodiffusion; immunoglobulin deficiency; ...
TD tabes dorsalis; tardive dyskinesia; T-cell dependent; temporary disability; terminal device; tetanus...
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
PF pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DLT Dose limiting toxicities
DLT Dose limiting toxicity
DLTs Dose-limiting toxicities
LD Limiting dilution
LDA Limiting dilution analyses
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • limiting factor
    ÇѰè ÀÎÀÚ, Á¦ÇÑ ÀÎÀÚ, ÇÑÁ¤ ÀÎÀÚ
  • limiting condition
    Á¦ÇÑ ¿äÀÎ
  • periventricular glial limiting membrane
    ³ú½Ç ÁÖÀ§ ¾Æ±³ °æ°è¸·
  • rate-limiting enzyme
    ¼Óµµ Á¶Àý È¿¼Ò
  • self-limiting
    ÀÚ±â ÇÑÁ¤¼º, ÀÚ±â ÇÑÁ¤Àû
    ¿ÜºÎÀÇ ¿µÇâ¿¡ ÀÇÇØ¼­°¡ ¾Æ´Ï¶ó, ÀÚ±â ÀÚ½ÅÀÇ Æ¯¼º¿¡ ÀÇÇØ¼­ ÇÑÁ¤µÈ, ÀÏÁ¤ÇÏ°Ô ÇÑÁ¤µÈ °æ°ú¸¦ ÃëÇÏ´Â Áúȯ¿¡ ´ëÇØ¼­ ¸»ÇÑ´Ù.
  • absorbed dose conversion factor
    Èí¼ö¼±·® º¯È¯ °è¼ö
  • dose modifying factor
    ¼±·® ¼ö½Ä °è¼ö
  • IGF-I : insulin like growth factor-IÀÇ ¾àÀÚ. ¼ºÀåÆÇÀÎ epiphyseal plate¿¡ ¿¬°ñ »ý¼ºÀ» Áõ°¡½ÃÄÑ »ÀÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

    IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡

    Àν¶¸°¾ç ¼ºÀå ÀÎÀÚ °áÇÕ ´Ü¹éÁú
    insulinelike growth factor binding
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • air dose
    °øÁß ¼±·®, °ø±âÁß ¼±·®
    ´Ù¸¥ ¹°Ã¼¿¡ ÀÇÇÑ »ê¶õ¼±À» Á¦¿ÜÇÑ °ø±â ÁßÀÇ ¼±·®. ÀϹÝÀûÀ¸·Î ¹°Ã¼ÀÇ Ç¥¸é¿¡ À־µµ, ¶Ç´Â »ýü Á¶Á÷ ³»ÀÇ ÀÏ Á¡¿¡¼­ÀÇ ¼±·®À¸·Î¼­µµ ¸ðµç »ê¶õ¼±ÀÇ ¿µÇâÀ» ¹Þ±â ¶§¹®¿¡ °øÁß ¼±·®º¸´Ù ¸¹¾ÆÁø´Ù.
  • average dose
    Æò±Õ ¿ë·®, Æò±Õ Á¶»ç·®
  • average maintenance dose
    µð±âÅ»¸®½º Æò±Õ À¯Áö·®
  • basal dose
    ±âº» ¼±·®
  • booster dose
    Ãß°¡ Á¢Á¾·®
  • committed effective dose equivalent
    ¿¹Å¹ À¯È¿ ¼±·® ´ç·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
limiting factor Environmental factor that limits the growth or activities of an organism or that restricts the size of a population or its geographical range.
(09 Oct 1997)
Abbe's law of limiting resolution <physics> For a periodic structure of units separated by distance d and obliquely illuminated by the unrefracted ray and one of the two diffracted rays (extremely oblique illumination).
Abbe applied the law of diffraction: d = 0.5 lambda /NA, where: lambda = wavelength of the monochromic light or shortest of mixed wavelengths NA = the limiting numerical aperture (NA) of objective or condenser.
(05 Aug 1998)
anterior limiting layer of cornea A transparent homogeneous acellular layer, 6 to 9 um thick, lying between the basal lamina of the outer layer of stratified epithelium and the substantia propria of the cornea; considered to be a basement membrane.
Synonym: lamina limitans anterior corneae, anterior elastic layer, Bowman's membrane, lamina elastica anterior, limiting layers of cornea.
(05 Mar 2000)
anterior limiting ring The periphery of the cornea marking the termination of Descemet's membrane and the anterior border of the trabecular meshwork; an important landmark in gonioscopy.
Synonym: Schwalbe's ring.
(05 Mar 2000)
rate-limiting step <biochemistry> The slowest step in a metabolic pathway, or the step in an enzymatic reaction that requires the greatest amount of energy to initiate.
(17 Dec 1997)
glial limiting membrane A dense, resilient membrane forming the true capsule of the brain and spinal cord, composed of the processes of astrocytes (macroglia cells) and covered throughout by the pia mater, which firmly adheres to it; the two membranes are collectively called the pial-glial membrane.
Synonym: membrana limitans gliae.
(05 Mar 2000)
posterior limiting layer of cornea A transparent homogeneous acellular layer between the substantia propria and the endothelial layer of the cornea; considered to be a highly developed basement membrane.
Synonym: lamina limitans posterior corneae, membrana vitrea, Descemet's membrane, Duddell's membrane, entocornea, hyaloid membrane, lamina elastica posterior, limiting layers of cornea, membrana hyaloidea, posterior elastic layer, tunica vitrea, vitreous membrane.
(05 Mar 2000)
internal limiting membrane Formed by the expanded inner ends of Muller's fibres, outer limiting membrane, not a membrane but a row of junctional complexes.
Synonym: membrana limitans.
(05 Mar 2000)
limiting angle The angle of incidence at which a ray of light, in passing between two media, changes from refraction to total reflection.
Synonym: limiting angle.
(05 Mar 2000)
limiting layers of cornea anterior limiting layer of cornea, posterior limiting layer of cornea
limiting membrane of retina One of two layers of the retina:
(05 Mar 2000)
limiting sulcus The medial longitudinal groove on the inner surface of the neural tube separating the alar and basal plates.
Synonym: sulcus limitans.
(05 Mar 2000)
limiting sulcus of Reil A saemicircular fissure demarcating the insula from the opercula above, below, and behind.
Synonym: sulcus circularis insulae, circular sulcus of Reil, limiting sulcus of Reil.
(05 Mar 2000)
limiting sulcus of rhomboid fossa A lateral groove running the whole length of the floor of the rhomboid fossa on either side of the midline, representing the remains of the sulcus demarcating the alar (dorsal) from the basal (ventral) plate of the embryonic rhombencephalon.
Synonym: sulcus limitans fossae rhomboideae.
(05 Mar 2000)
absorbed dose The amount of energy absorbed per unit mass of irradiated material at the target site; in radiation therapy, the former unit for absorbed dose is the rad; the current (S.I.) unit is the gray.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • limiting
    Á¦ÇÑÇÏ´Â;Á¦ÇÑÀû Çü¿ë»ç(¸í»ç¸¦ ÇÑÁ¤ÇÏ´À ±¸½Ç»ÓÀÎ this,some,certain µî)
  • dose
    ¾àÀÇ 1ȸºÐ;~¿¡ Åõ¾àÇÏ´Ù;º¹¿ë½ÃŰ´Ù
  • maximum dose
    (¾àÀÇ) ±Ø·®
  • minimum dose
    ÃÖ¼Ò Åõ¾à·®
  • factor
    ¿ä¼Ò,¿äÀÎ
  • F factor
    FÀÎÀÚ;¿°¼ºÀÎÀÚ
  • R factor
    R ÀÎÀÚ(¼¼±ÕÀÇ ¾àÁ¦ ³»¼º ÀÎÀÚ)
  • Rh factor
    ¸®¼­½º ÀÎÀÚ(ÀûÇ÷±¸ ¼Ó¿¡ ÀÖ´Â ÀÀÇ÷¼Ò)
  • Rhesus factor(antigen)
    =RH FACTOR
  • coal-factor
    ¼®Åº Áß°³ »óÀÎ(µµ¸Å »óÀÎ)
  • common factor
    =COMMON DIVISOR
  • conversion factor
    (¹®ÀÇ.ÀÚ·áû±¸¿¡¼­ ½ÇÁ¦ »óǰ±¸¸ÅÀÎÀ¸·ÎÀÇ)ÀüȯÀ²
  • factor
    ¿ä¼Ò;¿äÀÎ;¿øÀÎ;Àμö;ÀÎÀÚ;°è¼ö;À²;´ë¸®»ó;µµ¸Å»ó;Á߸ÅÀÎ
  • factor analysis
    ÀÎÀÚ ºÐ¼®
  • factor cost
    ¿äÀÎ(¿ä¼­)ºñ¿ë
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á